TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION
申请人:Napoletano Mauro
公开号:US20130079339A1
公开(公告)日:2013-03-28
The invention discloses compounds of formula I
wherein Y is a group of formula A, B, C, D, or E:
and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description.
The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.
TRPV1 vanilloid receptor antagonists with a bicyclic portion
申请人:Serentrix LLC
公开号:US10233177B2
公开(公告)日:2019-03-19
The invention discloses compounds of formula I
wherein Y is a group of formula A, B, C, D, or E:
and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description.
The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.
本发明公开了式 I 的化合物
其中 Y 是式 A、B、C、D 或 E 的基团:
和 W、Q、n、R1、R2、R3、U1-U5、J 和 K 的含义见说明。
式 I 的化合物是 TRPV1 拮抗剂,可用作药物组合物的活性成分,用于治疗疼痛和其他通过抑制类香草素受体 TRPV1 而改善的病症。
"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"
申请人:Pharmeste S.r.l.
公开号:EP2552888A1
公开(公告)日:2013-02-06
Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations
申请人:Gruenenthal GmbH
公开号:US20140179686A1
公开(公告)日:2014-06-26
The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.
TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion
申请人:Serentrix, LLC
公开号:US20160289199A1
公开(公告)日:2016-10-06
The invention discloses compounds of formula I
wherein Y is a group of formula A, B, C, D, or E:
and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description.
The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.